BayPAT’s Licensee Dualyx NV raises 40€ million to progress Treg therapies for autoimmune diseases into the clinic
-
BayPAT’s Licensee Dualyx NV raises 40€ million to progress Treg therapies for autoimmune diseases into the clinic
-
Patent Sales Agreement between BayPAT and Evonik 
Patent Sales Agreement between BayPAT and Evonik
-
New patent sales agreement between BayPAT and Reactive Robotics 
New patent sales agreement between BayPAT and Reactive Robotics
-
BayPAT’s Licensee Recardio and FDA reach agreement on Pivotal Phase 3 Regenerative Post-Myocardial Infarction Trial Design for Dutogliptin 
BayPAT’s Licensee Recardio and FDA reach agreement on Pivotal Phase 3 Regenerative Post-Myocardial Infarction Trial Design for Dutogliptin
-
BayPAT entered into an exclusive license agreement with Orbem 
BayPAT entered into an exclusive license agreement with Orbem
-
BayPAT entered into an exclusive license agreement with Carina Biotech 
BayPAT entered into an exclusive license agreement with Carina Biotech
-
BayPAT entered into an exclusive license agreement with TRIMT 
BayPAT entered into an exclusive license agreement with TRIMT
-
BayPAT’s Licensee Recardio already in Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin in Europe and USA 
BayPAT’s Licensee Recardio already in Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin in Europe and USA
-
E.ON Energy Projects Acquires Energy Technology from BayPAT
E.ON Energy Projects Acquires Energy Technology from BayPAT
-
BayPAT's Licensee Scintomics signed Sub-License Agreement
BayPAT's Licensee Scintomics signed Sub-License Agreement
-
BayPAT out-licenses three novel radioligands to Scintomics 
BayPAT out-licenses three novel radioligands to Scintomics
-
Startup Company Bitflux acquires technology from BayPAT 
Startup Company Bitflux acquires technology from BayPAT
-
License for indoor navigation 
License for indoor navigation
